Our findings establish SLC7A11 as a powerful prognostic biomarker for HCC, unveil its role in shaping an immunosuppressive TME, and highlight its value in predicting response to conventional and emerging therapies, providing a rationale for targeting SLC7A11 in future treatment strategies. This evidence concerns the gene SLC7A11 and hepatocellular carcinoma.